




RealRate

PHARMACEUTICAL 2020

Adamas Pharmaceuticals Inc
Rank 228 of 362



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2020

Adamas Pharmaceuticals Inc Rank 228 of 362

The relative strengths and weaknesses of Adamas Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Adamas Pharmaceuticals Inc compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 107% points. The greatest weakness of Adamas Pharmaceuticals Inc is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 147% points.

The company's Economic Capital Ratio, given in the ranking table, is -263%, being 40% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	150,320
Cost of Goods Sold	2,469
Intangible Assets	0
Liabilities, Current	26,948
Liabilities, Non-Current	136,103
Other Assets	9,389
Other Compr. Net Income	280
Other Expenses	12,951
Other Liabilities	0
Other Net Income	0
Property and Equipment	2,449
Research and Development	30,034
Revenues	54,637
Selling, General and Administrative Expense	114,369

Output Variable	Value in 1000 USD
Assets	162,158
Liabilities	163,051
Expenses	159,823
Stockholders Equity	-893
Net Income	-105,186
Comprehensive Net Income	-105,046
Economic Capital Ratio	-263%

